首頁 > 市場調查報告書 > 製藥

消化器孤兒藥

市場調查報告書

商品編碼

1830994

克隆氏症治療市場

Crohn's Disease Therapeutics Market

出版日期: 2025年09月24日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

2024 年克隆氏症治療市場價值為 102.3 億美元，預計到 2031 年將達到 133.3 億美元，2025 年至 2031 年的複合年成長率預計為 4.1%。

市場洞察與分析師觀點：克隆氏症是一種慢性發炎性疾病，主要影響胃腸道，尤其是迴腸末端和結腸起始部。此病以消化道內壁發炎為特徵，導致腹部不適、腹瀉和營養不良等症狀。克隆氏症治療市場的擴張很大程度源自於西方國家（尤其是美國）克隆氏症發病率的上升。此外，企業為維持市場競爭力所採取的策略性措施也推動著市場成長。在預測期內，先進醫療器材的採用率顯著上升，預計將為克隆氏症治療市場帶來新的趨勢。

成長動力與挑戰：克隆氏症被歸類為腸躁症，這是一種尚無明確治癒方法的慢性發炎性腸道疾病。此疾病的確切病因尚不清楚，但主要歸因於腸道對藥物、毒素、感染和腸道微生物等各種因素產生的不適當免疫反應，尤其是在有遺傳易感性的人群中。根據美國國家醫學圖書館的數據，克隆氏症 (CD) 在西方已開發國家更為常見，尤其是在北美、北歐和紐西蘭。此病通常發生在 15 至 30 歲和 40 至 60 歲之間，在城市地區發病率更高。北歐血統和猶太血統的人群發生率尤其高，約為千分之 3.2。然而，最近的研究表明，亞洲、非洲和澳大拉西亞的發病率顯著上升，這可能是由於這些地區的快速工業化。因此，這些地區克隆氏症的驚人盛行率正在推動克隆氏症治療市場的成長。

根據美國國立衛生研究院報告，克隆氏症造成了巨大的經濟負擔，在歐洲，每位患者每年的直接醫療費用平均約為3500美元。每10萬人中約有322人受此病影響，但各國的盛行率差異很大。超過一半的克隆氏症患者可能未確診，或表現出與其他消化系統疾病相似的症狀。此病在女性中較為常見，每1名男性患者對應3名女性。

專注於開發腸躁症治療方法的製藥公司正在積極進行宣傳活動，旨在透過向大眾普及症狀、診斷和治療方案，有效管理此症候群。 2018年，艾爾建公司 (Allergan PLC) 與 Ironwood 合作推出了一個互動式數位目的地平台，旨在幫助個人自我學習並採取行動應對消化系統疾病。因此，腸躁症盛行率的上升是克隆氏症治療市場成長的關鍵驅動力。

策略洞察報告細分和範圍：克隆氏症治療市場分析涵蓋多個細分領域，包括藥物類型、配銷通路和地理。依藥物類別，市場分為抗發炎藥、免疫系統抑制劑、抗生素、生物製劑、止瀉藥和止痛藥。生物製劑領域在2023年佔據最大市場佔有率，而抗發炎藥領域預計將在2023年至2031年期間實現最高複合年成長率。

就終端用戶而言，市場細分為醫院藥房、臨床藥房和線上平台。 2023年，醫院藥局佔據了克隆氏症治療市場的最大佔有率。報告涵蓋以下地區的克隆氏症治療市場：北美（美國、加拿大和墨西哥）、歐洲（西班牙、英國、德國、法國、義大利和歐洲其他地區）、亞太地區（韓國、中國、日本、印度、澳洲和亞太其他地區）、中東和非洲（南非、沙烏地阿拉伯、阿拉伯聯合大公國和中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲（巴西、阿根廷和南美洲和其他地區）。

區域分析：北美是全球克隆氏症治療市場成長的主要貢獻者。預計亞太地區在2023年至2031年期間的複合年成長率最高。北美市場的成長動力包括：慢性病盛行率的上升、技術進步和創新醫療產品的普及、老齡人口的成長，以及參與新產品和現有產品開發的關鍵市場參與者的出現。 2023年，美國佔據了北美克隆氏症治療市場的最大佔有率。

克隆氏症治療市場報告範圍：產業發展與未來機會：克隆氏症治療市場的預測是基於各種二手和一手研究成果，包括主要公司出版物、協會資料和資料庫。根據公司新聞稿，克隆氏症治療市場主要參與者的重大進展包括：

2023 年，美國食品藥物管理局 (FDA) 批准了 Rinvoq (upadacitinib)，這是第一種用於治療中度至重度克隆氏症的口服藥物，適用於對 TNF 阻斷藥物候選物反應不足的成年患者。 2022 年，FDA 批准 Skyrizi 用於治療中度至重度活動性克隆氏症成年患者。 2021 年，艾伯維公司宣布啟動 risankizumab 的 3 期臨床試驗，risankizumab 是一種針對白介素 23 (IL-23) 通路的人源化單株抗體，旨在評估其對中度至重度克隆氏症患者的療效和安全性。 2021 年，武田藥品工業株式會社啟動了口服化合物 TAK-721（趨化因子受體 CXCR3 的選擇性拮抗劑）的 3 期試驗，以評估其對中度至重度克隆氏症。競爭格局和主要公司：克隆氏症治療市場的主要參與者包括 Abbvie, Inc.；強生私人有限公司；葛蘭素史克公司；默克公司；諾華公司；新基公司；基因泰克；輝瑞公司；雀巢健康科學；以及勃林格殷格翰有限公司。此外，還分析了其他幾家公司，以提供對市場及其生態系統的全面概述。這些公司專注於地理擴張和新產品發布，以滿足全球消費者日益成長的需求，並透過專業產品組合拓寬其產品供應。他們的國際影響力使他們能夠滿足龐大的客戶群，從而促進市場成長。

Market Insights and Analyst View:Crohn's disease is a chronic inflammatory disorder that mainly impacts the gastrointestinal tract, particularly the terminal ileum and the beginning of the colon. This condition is marked by inflammation of the digestive tract lining, resulting in symptoms such as abdominal discomfort, diarrhea, and malnutrition. The expansion of the Crohn's disease therapeutics market is largely due to the rising incidence of the disease in Western nations, especially in the US. Furthermore, strategic initiatives by companies to maintain competitiveness in the market are driving growth. A notable rise in the adoption of advanced medical devices is expected to introduce new trends in the Crohn's disease therapeutics market during the forecast period.

Growth Drivers and Challenges:Crohn's disease is classified as an irritable bowel syndrome, a chronic inflammatory bowel disorder without a definitive cure. The precise cause of this condition remains unclear, but it is primarily attributed to an inappropriate immune response in the bowel to various factors such as drugs, toxins, infections, and intestinal microbes, particularly in genetically predisposed individuals. According to the National Library of Medicine, Crohn's disease (CD) is more prevalent in developed Western countries, notably in North America, northern Europe, and New Zealand. The onset of the disease typically occurs in individuals aged 15 to 30 and 40 to 60 years, with a higher prevalence in urban settings. The incidence rate is particularly high among individuals of northern European descent and Jewish ancestry, at approximately 3.2 per 1,000. However, recent research indicates a significant rise in incidence in Asia, Africa, and Australasia, likely due to rapid industrialization in these regions. Consequently, the alarming prevalence of Crohn's disease in these areas is propelling the growth of the Crohn's disease therapeutics market.

As reported by the National Institute of Health, Crohn's disease imposes a considerable economic burden, with direct healthcare costs averaging around US$ 3,500 per patient annually in Europe. The disease affects roughly 322 individuals per 100,000, although prevalence rates can differ significantly between countries. More than half of Crohn's disease patients may remain undiagnosed or exhibit symptoms similar to other digestive disorders. The condition is more frequently observed in women, with a ratio of three women affected for every man.

Pharmaceutical companies focused on developing treatments for irritable bowel syndrome are actively implementing awareness initiatives aimed at effectively managing this syndrome by educating the public about symptoms, diagnosis, and treatment options. In 2018, Allergan PLC and Ironwood collaborated to launch an Interactive Digital Destination platform designed to empower individuals to educate themselves and take action against digestive disorders. Thus, the increasing prevalence of irritable bowel syndrome is a key driver of growth in the Crohn's disease therapeutics market.

Strategic Insights

Report Segmentation and Scope:The analysis of the Crohn's disease therapeutics market has been conducted by examining various segments, including drug type, distribution channel, and geography. By drug class, the market is categorized into anti-inflammatory drugs, immune system suppressors, antibiotics, biologics, anti-diarrheal medications, and pain relievers. The biologics segment held the largest market share in 2023, while the anti-inflammatory drugs segment is projected to achieve the highest CAGR from 2023 to 2031.

In terms of end users, the market is segmented into hospital pharmacies, clinical pharmacies, and online platforms. The hospital pharmacy segment represented the largest share of the Crohn's disease therapeutics market in 2023. Geographically, the report covers the Crohn's disease therapeutics market in North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, Japan, India, Australia, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, UAE, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Regional Analysis:North America is the leading contributor to the global growth of the Crohn's disease therapeutics market. The Asia Pacific region is expected to exhibit the highest CAGR during the period from 2023 to 2031. The market growth in North America is driven by the increasing prevalence of chronic diseases, advancements in technology and access to innovative medical products, a growing elderly population, and the presence of key market players engaged in both new and existing product development. In 2023, the US accounted for the largest share of the Crohn's disease therapeutics market in North America.

Crohns Disease Therapeutics Market Report Scope

Industry Developments and Future Opportunities:The forecast for the Crohn's disease therapeutics market is based on a combination of various secondary and primary research findings, including key company publications, association data, and databases. According to company press releases, significant developments by major players in the Crohn's disease therapeutics market include:

In 2023, the US Food and Drug Administration (FDA) approved Rinvoq (upadacitinib), the first oral pill for treating moderate-to-severe Crohn's disease, intended for adult patients who have not responded adequately to TNF-blocking drug candidates.

In 2022, the FDA granted approval for Skyrizi for the treatment of adults with moderate-to-severe active cases of Crohn's disease.

In 2021, AbbVie Inc. announced the start of a Phase 3 trial for risankizumab, a humanized monoclonal antibody targeting the interleukin-23 (IL-23) pathway, aimed at assessing its efficacy and safety in patients with moderate-to-severe Crohn's disease.

In 2021, Takeda Pharmaceutical Company Limited initiated a Phase 3 trial for the oral compound TAK-721, a selective antagonist of the chemokine receptor CXCR3, to evaluate its efficacy and safety in patients with moderate-to-severe Crohn's disease.

Competitive Landscape and Key Companies:Key players in the Crohn's disease therapeutics market include Abbvie, Inc.; Johnson and Johnson Private Limited; GlaxoSmithKline Plc; Merck and Co., Inc.; Novartis Ag; Celgene Corporation; Genentech; Pfizer Inc.; Nestle Health Science; and Boehringer Ingelheim GmbH. Additionally, several other companies have been analyzed to provide a comprehensive overview of the market and its ecosystem. These companies are focusing on geographic expansion and new product launches to meet the increasing demand from consumers globally and to broaden their product offerings with specialized portfolios. Their international presence enables them to cater to a large customer base, thereby facilitating market growth.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Crohn’s Disease Therapeutics Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Crohn’s Disease Therapeutics Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Crohn’s Disease Therapeutics Market - Global Market Analysis

6.1 Crohn’s Disease Therapeutics - Global Market Overview
6.2 Crohn’s Disease Therapeutics - Global Market and Forecast to 2031

7. Crohn’s Disease Therapeutics Market - Revenue Analysis (USD Million) - By Drug Class, 2021-2031

7.1 Overview
7.2 Anti-inflammatory Drugs
7.3 Immune System Suppressors
7.4 Antibiotics
7.5 Biologics
7.6 Anti-diarrheal
7.7 Pain Relievers

8. Crohn’s Disease Therapeutics Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

8.1 Overview
8.2 Hospital Pharmacy
8.3 Retail Pharmacy
8.4 Online Pharmacy

9. Crohn’s Disease Therapeutics Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

9.1 North America
- 9.1.1 North America Crohn’s Disease Therapeutics Market Overview
- 9.1.2 North America Crohn’s Disease Therapeutics Market Revenue and Forecasts to 2031
- 9.1.3 North America Crohn’s Disease Therapeutics Market Revenue and Forecasts and Analysis - By Drug Class
- 9.1.4 North America Crohn’s Disease Therapeutics Market Revenue and Forecasts and Analysis - By Distribution Channel
- 9.1.5 North America Crohn’s Disease Therapeutics Market Revenue and Forecasts and Analysis - By Countries
  - 9.1.5.1 United States Crohn’s Disease Therapeutics Market
    - 9.1.5.1.1 United States Crohn’s Disease Therapeutics Market, by Drug Class
    - 9.1.5.1.2 United States Crohn’s Disease Therapeutics Market, by Distribution Channel
  - 9.1.5.2 Canada Crohn’s Disease Therapeutics Market
    - 9.1.5.2.1 Canada Crohn’s Disease Therapeutics Market, by Drug Class
    - 9.1.5.2.2 Canada Crohn’s Disease Therapeutics Market, by Distribution Channel
  - 9.1.5.3 Mexico Crohn’s Disease Therapeutics Market
    - 9.1.5.3.1 Mexico Crohn’s Disease Therapeutics Market, by Drug Class
    - 9.1.5.3.2 Mexico Crohn’s Disease Therapeutics Market, by Distribution Channel
9.2 Europe
- 9.2.1 Germany
- 9.2.2 France
- 9.2.3 Italy
- 9.2.4 Spain
- 9.2.5 United Kingdom
9.3 Asia-Pacific
- 9.3.1 Australia
- 9.3.2 China
- 9.3.3 India
- 9.3.4 Japan
- 9.3.5 South Korea
9.4 Middle East and Africa
- 9.4.1 South Africa
- 9.4.2 Saudi Arabia
- 9.4.3 U.A.E
9.5 South and Central America
- 9.5.1 Brazil
- 9.5.2 Argentina

10. Industry Landscape

10.1 Mergers and Acquisitions
10.2 Agreements, Collaborations, Joint Ventures
10.3 New Product Launches
10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration

12. Crohn’s Disease Therapeutics Market - Key Company Profiles

12.1 Abbvie, Inc.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Johnson and Johnson Private Limited
12.3 GlaxoSmithKline plc
12.4 Merck and CO., Inc.
12.5 Novartis AG.
12.6 Celgene Corporation
12.7 Genetech
12.8 Pfizer Inc.
12.9 Nestl
12.10 Boehringer Ingelheim GmbH